模式识别受体在HBV感染过程中的作用研究进展

doi:10.3969/j.issn.1672-5069.2016.06.035

摘要/Abstract

摘要： 乙型肝炎病毒感染后常可导致慢性乙型肝炎。机体模式识别受体（PRRs）作为一类重要的识别分子，在病毒感染早期可识别病原体并诱导抗病毒免疫应答。本文阐述了PRRs的定义、种类和信号通路，将其分为Toll样受体家族和Toll非依赖性模式识别受体家族，介绍了其与乙型肝炎病毒感染之间的关系。

关键词: 乙型肝炎病毒, 模式识别受体, Toll样受体

Abstract: Hepatitis B virus （HBV） often leads to chronic hepatitis B. Pattern recognition receptors （PRRs）， an important recognition molecules，play a pivotal role in recognizing pathogen and inducing antiviral immune response since the early stage of virus infection. In this review，we expounded the definition，types，and signal paths of PRRs，which were divided into Toll-like receptors and Toll-independent pattern recognition receptors，and we finally summarized the roles of PRRs in the process of HBV infection.

Key words: Hepatitis B virus, Pattern recognition receptors, Toll-like receptors

朱甜甜综述，李军，朱传龙审校. 模式识别受体在HBV感染过程中的作用研究进展[J]. 实用肝脏病杂志, 2016, 19(6): 749-752.

Zhu Tiantian，Li Jun，Zhu Chuanlong.. Pattern recognition receptors in HBV infection[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 749-752.

参考文献

[1] Zhang X，Ma Z，Liu H，et al. Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol，2012，57（3）:522-528.
[2] Ait-Goughoulte M，Lucifora J，Zoulim F，et al. Innate antiviral immune responses to hepatitis B virus. Viruses，2010，2（7）:1394-1410.
[3] Pei RJ，Chen XW，Lu MJ. Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways. World J Gastroenterol，2014，20（33）:11618-11629.
[4] Broering R，Lu M，Schlaak J F. Role of Toll-like receptors in liver health and disease. Clin Sci（Lond），2011，121（10）:415-426.
[5] 李红霞，潘晨，陈立，等. Toll样受体与慢性乙型肝炎的研究进展. 国际流行病学传染病学杂志，2010，37（3）:195-198.
[6] Palumbo GA，Scisciani C，Pediconi N，et al. IL6 inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome. Plos One，2015，10（11）:e0142599.
[7] Akira S，Takeda K. Toll-like receptor signaling. Nat Rev Immunol，2004，4:499-511.
[8] Takeda K，Kaisho T，Akira S. Toll-like receptors. Annu Rev Immunol，2003，21:335-376.
[9] Akira S，Uematsu S，Takeuchi O. Pathogen recognition and innate immunity. Cell，2006，124（4）:783-801.
[10] Bertoletti A，Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections:towards restoration of immune control of viral infection. Commun Soil Sci Plan，2013， 61（12）:438-444.
[11] Guo H，Jiang D，Ma D，et al. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol，2009，83(2）:847-858.
[12] Seki E，Brenner DA.Toll-like receptors and adaptor molecules in liver disease:update. Hepatology，2008，48（1）:322-335.
[13] Hosel M，Quasdorff M，Wiegmann K，et al. Not interferon，but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology，2009，50（6）:1773-1782.
[14] Zhang E，Lu M. Toll-like receptor（TLR）-mediated innate immune responses in the control of hepatitis B virus （HBV）infection. Med Microbiol Immun，2015，204（1）:11-20.
[15] Honda K，Taniguchi T. IRFs:master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol，2006，6（9）:644-658.
[16] Wu J，Meng Z，Jiang M，et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells.Hepatology，2009，49（4）:1132-1140.
[17] Wu J，Meng Z，Jiang M，et al. Toll-like receptor-induced innate immune responses in non parenchymal liver cells are cell type-specific.Immunology，2009，129（3）:363-374.
[18] Shi B，Ren G，Hu Y，et al. HBsAg inhibits IFN-α production in plasmacytoid dendritic cells through TNF-α and IL-10 induction in monocytes. Plos One，2012，7（9）:e44900.
[19] Romagne F. Current and future drugs targeting one class of innate immunity receptors:the Toll-like receptors. Drug Discov，2007，12（1-2）:80-87.
[20] Loo YM，Gale M. Immune signaling by RIG-I-like receptors. Immunity，2011，34（5）:680-692.
[21] Wieland SF，Eustaquio A，Whittenbauer C，et al. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Pro Natl Acad Sci USA，2005，102（28）:9913-9917.
[22] Akira S，Uematsu S，Takeuchi O. Pathogen Recognition and Innate Immunity. Cell，2006，124（4）:783-801.
[23] Lee MS，Kim YJ. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem，2007，76（76）:447-480.
[24] Komai-Koma M，Jones L，Ogg GS，et al. TLR2 is expressed on activated T cells as a costimulatory receptor. Pro Natl Acad Sci USA，2004，101（9）:3029-3034.
[25] Mercier BC，Cottalorda A，Coupet CA，et al. TLR2 engagement on CD8 T cells enables generation of functional memory cells in response to a suboptimal TCR signal. J Immunol，2009，182（4）:1860-1867.
[26] Lanford RE，Guerra B，Chavez D，et al. GS-9620，an oral agonist of Toll-like receptor-7，induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology，2013，144（7）:1508-1517.
[27] Fosdick A，Zheng J，Pflanz S，et al. Pharmacokinetic and pharmacodynamic properties of GS-9620，a novel Toll-like receptor 7 agonist，demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther，2014，348（1）:96-105.
[28] Jo J，Tan AT，Ussher JE，et al. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. Plos Pathog，2014，10（6）:e1004210.
[29] Sawhney R，Visvanathan K. Polymorphisms of toll-like receptors and their pathways in viral hepatitis. Antiv Ther，2011，16（4）:443-458.
[30] Xu N，Yao HP，Lyu GC，et al. Downregulation of TLR7/9 leads to deficient production of IFN-α from plasmacytoid dendritic cells in chronic hepatitis B. Inflamm Res，2012，61（9）:997-1004.
[31] Ning L，Qian L，Qian Z，et al. Impaired TLR3/IFN-β signaling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure:Relevance to the severity of liver damage. Biochem Biophys Res Commun，2009，390（3）:630-635.
[32] Vincent E，Zannetti C，Lucifora J，et al. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One，2011，6（10）:e26315.
[33] Dienstag JL. Hepatitis B virus infection. N Engl J Med，2008，359（14）:1486-1500.
[34] Jiang M，Broering R，Trippler M，et al. Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen. J Viral Hepat，2014，21（12）:860-872.
[35] Wang S，Chen Z，Hu C，et al. Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. J Immunol，2013，190（10）:5142-5151.
[36] Visvanathan K，Skinner NA，Thompson AJ， et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein.Hepatology，2007，45（1）:102-110.
[37] Lang T，Lo C，Skinner N，et al. The hepatitis B e antigen （HBeAg） targets and suppresses activation of the Toll-like receptor signaling pathway. J Hepatol，2011，55（4）:762-769.
[38] Wu M，Xu Y，Lin S，et al. Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat 1. J Gen Virol，2007，88（12）:3260-3269.
[39] Yu S，Chen J，Wu M，et al. Hepatitis B virus polymerase inhibits RIG-I-and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and D. J Gen Virol，2010，91（Pt 8）:2080-2090.
[40] Chen J，Wu M，Zhang X，et al. Hepatitis B virus polymerase impairs interferon-α-induced STA T activation through inhibition of importin-α5 and protein kinase C-δ. Hepatology，2013，57（2）:470-482.
[41] Zhang ZH，Wu CC，Chen XW，et al. Genetic variation of hepatitis B virus and its significance for pathogenesis. World J Gastroenterol，2016，22（1）:126-144.
[42] Protzer U，Maini MK，Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol，2012，12:201-213.
[43] Al-Qahtani A，Al-Ahdal M，Abdo A，et al. Toll-like receptor 3 polymorphism and its association with hepatitis B virus infection in Saudi Arabian patients. J Med Virol，2012，84（9）:1353-1359.
[44] Shahrakyvahed A，Sanchooli J，Sanadgol N，et al. TLR9:an important molecule in the fight against hepatitis B virus. Postgrad Med J，2014，90（1065）:396-401.
[45] Liu HY，Zhang XY. Innate immune recognition of hepatitis B virus. World J Hepatol，2015，7（21）:2319-2322.
[46] Sato S，Li K，Kameyama T，et al. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity，2015，42（1）:1-10.
[47] Ebrahim M，Mirzaei V，Bidaki R，et al. Are RIG-1 and MDA5 expressions associated with chronic HBV infection. Viral Immunol，2015，28（9）:504-508.
[48] Lu HL，Liao F. Melanoma differentiation-associated gene 5 senses hepatitis B virus and activates innate immune signaling to suppress virus replication. J Immunol，2013，191（6）:3264-3276.
[49] Zhu C,Xiao F,Lin W. EFTUD2 on innate immunity. Oncotarget， 2015，6:32313-32314.